Plexus (PLXS) Q1 2026 earnings review
Revenue Growth Accelerates, But Cash Flow Burns in Q1
Plexus delivered a solid start to Fiscal 2026, meeting the high end of EPS guidance with $1.78 (Non-GAAP). The narrative has shifted decisively to growth: revenue increased 10% YoY to $1.07B, snapping a trend of stagnation. However, this growth came at a cost to liquidity—Free Cash Flow swung to negative $50.6M as the company invested heavily in working capital to support program ramps. While Healthcare (+25% YoY) and Aerospace are surging, the Industrial segment remains a drag, shrinking 4%. Guidance for Q2 implies further acceleration to ~15% YoY growth, suggesting management is confident the inventory investments will convert to sales quickly.
🐂 Bull Case
Plexus won 22 manufacturing programs representing $283M in annualized revenue. Crucially, Aerospace/Defense wins hit a record $220M, signaling strong future visibility despite current supply chain complexities.
The Healthcare/Life Sciences segment is outperforming significantly, growing 25% YoY to $466M. This high-complexity, sticky revenue stream now constitutes 43% of total sales, improving the overall portfolio mix.
🐻 Bear Case
Free Cash Flow collapsed to negative $50.6M in Q1 from positive levels in FY25. While management reiterated full-year guidance of $100M FCF, this implies the company must generate ~$150M in the remaining three quarters—a steep hill to climb.
Despite talk of semi-cap strength, the aggregate Industrial segment revenue fell 3.6% YoY. This segment accounts for 40% of revenue, and its continued contraction drags on the corporate growth rate.
⚖️ Verdict: 🟢
Accelerating. The top-line inflection is real, supported by strong guidance and record wins. The cash burn is a concern but appears aligned with the specific working capital needs of new program ramps. If Industrial stabilizes, the growth story is compelling.
Key Themes
Free Cash Flow Reversal
After a strong FY25 for cash generation ($154M total), Q1 F26 saw a sharp reversal to negative $50.6M. Operating Cash Flow was negative $15.4M. Management attributes this to working capital investments for ramps, but the pressure is evident: Days in Inventory rose sequentially to 124 days from 118 in Q4. To hit the FY26 target of $100M FCF, execution in working capital management must be flawless for the rest of the year.
Healthcare/Life Sciences Expansion
This segment has become the primary growth engine, surging 24.6% YoY to $466M. It has overtaken Industrial to become the largest revenue contributor (43% of total). Momentum is driven by new program ramps in imaging and monitoring sub-sectors, offsetting softer industrial demand.
Record Aerospace/Defense Wins
The Aerospace/Defense sector delivered record quarterly manufacturing wins of $220M in annualized revenue. This indicates a massive pipeline fill that validates the company's strategy in commercial space and defense technologies, securing revenue layers for FY27 and beyond.
Industrial Segment Drag
Despite management highlighting 'market share gains' in semi-cap, the actual data shows the Industrial segment declining nearly 4% YoY. This contradicts the broader growth narrative and suggests significant weakness in other industrial sub-sectors (likely communications/broadband) is overpowering the semi-cap gains.
Margin Stability Amidst Growth
Non-GAAP Operating Margin came in at 5.8%, down slightly from 6.0% a year ago but meeting guidance. Guidance for Q2 (5.6% - 6.0%) suggests margins are stable but capped by the costs associated with ramping new programs and the new Penang facility. There is no immediate operating leverage visible in the margin percentages despite the 10-15% revenue growth.
Share Repurchase Continuation
Plexus repurchased $22.4M of shares in Q1 at an average price of $146.36. While positive, the negative cash flow meant these buybacks were effectively funded by drawing down cash balances (Cash dropped from $306M to $248M). $62.6M remains on the authorization.
Other KPIs
Stable. Down from 14.6% in the prior quarter (25Q4) but remains healthy and well above the weighted average cost of capital (9.0%). The economic return of 4.2% demonstrates value creation despite the heavy investment cycle.
Deteriorating. Increased from 118 days in 25Q4 and remains elevated relative to the cash cycle target. This build-up is the primary culprit for the negative free cash flow and warrants close monitoring in Q2 to ensure it is actually 'ramp-related' and not stranded inventory.
GAAP tax expense was $9.85M on $51M income. This is higher than the single-digit rates seen in some prior periods (e.g., 25Q4 was aided by discrete items), normalizing back to the upper teens range.
Guidance
Accelerating. The midpoint ($1.13B) implies ~15% YoY growth (vs $980M in 25Q2) and ~6% sequential growth. This confirms the 'ramp' narrative is materializing faster than the general market recovery.
Accelerating. Midpoint of $1.875 represents ~13% YoY growth vs $1.66 in 25Q2. The growth in earnings is roughly matching revenue growth, indicating neutral operating leverage.
Stable. Consistent with Q1 results (5.8%) and Q2 25 results (5.7%). Management is prioritizing growth and market share capture over immediate margin expansion.
Key Questions
Bridge to Positive Cash Flow
Q1 Free Cash Flow was -$50M, yet you reiterated the $100M FY26 target. This requires generating ~$150M in the next three quarters. What specific working capital unwinds or inventory reductions are planned to bridge this massive gap?
Industrial Segment Weakness
Industrial revenue fell 4% YoY despite the narrative of semi-cap share gains. Which specific sub-sectors within Industrial are deteriorating enough to offset the semi-cap wins, and when do you expect the aggregate segment to return to growth?
Margin Leverage
With revenue growth accelerating to 15% YoY in Q2 guidance, why is the operating margin guide (midpoint 5.8%) essentially flat? When should investors expect the volume leverage to translate into margins breaking above the 6% ceiling?